These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 30107993

  • 1. Immunogenicity and protective efficacy of monovalent PCVs containing 22F and 33F polysaccharides in mouse models of colonization and co-infection.
    Khan MN, Pryharski K, Pichichero ME.
    Vaccine; 2018 Sep 11; 36(38):5701-5708. PubMed ID: 30107993
    [Abstract] [Full Text] [Related]

  • 2. Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.
    Kaur R, Pham M, Pichichero M.
    Vaccine; 2021 Jun 29; 39(29):3900-3906. PubMed ID: 34116872
    [Abstract] [Full Text] [Related]

  • 3. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM, Indrawati L, Cannon J, Blue J, Winters M, Macnair J, Pujar N, Manger W, Zhang Y, Antonello J, Shiver J, Caulfield M, Heinrichs JH.
    Vaccine; 2011 Nov 08; 29(48):8870-6. PubMed ID: 21964055
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Matur RV, Thuluva S, Gunneri S, Yerroju V, Reddy Mogulla R, Thammireddy K, Paliwal P, Mahantshetty NS, Ravi MD, Prashanth S, Verma S, Narayan JP.
    Vaccine; 2024 May 10; 42(13):3157-3165. PubMed ID: 38637211
    [Abstract] [Full Text] [Related]

  • 5. Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection.
    Khan MN, Xu Q, Pichichero ME.
    Infect Immun; 2017 Feb 10; 85(2):. PubMed ID: 27895132
    [Abstract] [Full Text] [Related]

  • 6. Anti-capsular immunity to Streptococcus pneumoniae serotype 22F prevents bacterial transmission in murine colonization and influenza virus co-infection models.
    Schmit T, Kuntz M, Patel D, Nadeem Khan M.
    Vaccine; 2021 Jan 15; 39(3):469-472. PubMed ID: 33349459
    [Abstract] [Full Text] [Related]

  • 7. PCR-based discrimination of emerging Streptococcus pneumoniae serotypes 22F and 33F.
    Gillis HD, Demczuk WHB, Griffith A, Martin I, Warhuus M, Lang ALS, ElSherif M, McNeil SA, LeBlanc JJ.
    J Microbiol Methods; 2018 Jan 15; 144():99-106. PubMed ID: 29162393
    [Abstract] [Full Text] [Related]

  • 8. The future of pneumococcal disease prevention.
    Rodgers GL, Klugman KP.
    Vaccine; 2011 Sep 14; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [Abstract] [Full Text] [Related]

  • 9. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Amin-Chowdhury Z, Groves N, Sheppard CL, Litt D, Fry NK, Andrews N, Ladhani SN.
    Vaccine; 2021 Apr 01; 39(14):1997-2004. PubMed ID: 33715901
    [Abstract] [Full Text] [Related]

  • 10. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.
    Saeland E, Jakobsen H, Ingolfsdottir G, Sigurdardottir ST, Jonsdottir I.
    J Infect Dis; 2001 Jan 15; 183(2):253-260. PubMed ID: 11110649
    [Abstract] [Full Text] [Related]

  • 11. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R, Meulen AS, Folkerth SD, Hoekstra JA, Dallas M, Hoover PA, Marchese RD, Zacholski DM, Watson WJ, Stek JE, Hartzel JS, Musey LK.
    Vaccine; 2015 Jun 04; 33(24):2793-9. PubMed ID: 25913828
    [Abstract] [Full Text] [Related]

  • 12. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.
    Clin Microbiol Infect; 2013 Oct 04; 19 Suppl 1():1-9. PubMed ID: 24083785
    [Abstract] [Full Text] [Related]

  • 13. Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F.
    Golden AR, Adam HJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance (CARA).
    Vaccine; 2016 May 17; 34(23):2527-30. PubMed ID: 27085174
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
    Xie J, Zhang Y, Caro-Aguilar I, Indrawati L, Smith WJ, Giovarelli C, Winters MA, MacNair J, He J, Abeygunawardana C, Musey L, Kosinski M, Skinner JM.
    Pediatr Infect Dis J; 2020 Jan 17; 39(1):70-77. PubMed ID: 31725555
    [Abstract] [Full Text] [Related]

  • 15. Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018.
    Golden AR, Fear T, Baxter M, Adam HJ, Martin I, Demczuk W, Karlowsky JA, Zhanel GG, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2021 Oct 17; 101(2):115447. PubMed ID: 34192638
    [Abstract] [Full Text] [Related]

  • 16. Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody.
    Doyle CR, Pirofski LA.
    mBio; 2016 Feb 02; 7(1):e02260-15. PubMed ID: 26838726
    [Abstract] [Full Text] [Related]

  • 17. Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018.
    Golden AR, Adam HJ, Baxter M, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Zhanel GG, Canadian Antimicrobial Resistance Alliance (CARA).
    Vaccine; 2021 Sep 15; 39(39):5474-5483. PubMed ID: 34454785
    [Abstract] [Full Text] [Related]

  • 18. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.
    Clin Infect Dis; 2013 Oct 15; 57(7):952-62. PubMed ID: 23804191
    [Abstract] [Full Text] [Related]

  • 19. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT, Cleary DW, Jefferies JM, Anderson R, Morris DE, Tuck AC, Gladstone RA, O'Doherty G, Kuruparan P, Bentley SD, Faust SN, Clarke SC.
    Vaccine; 2017 Mar 01; 35(9):1293-1298. PubMed ID: 28161425
    [Abstract] [Full Text] [Related]

  • 20. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
    Park C, Kwon EY, Choi SM, Cho SY, Byun JH, Park JY, Lee DG, Kang JH, Shin J, Kim H.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1169-1176. PubMed ID: 27960627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.